search
Back to results

Self-Management in Young Adults With Type 1 Diabetes (SLEEPT1D)

Primary Purpose

Type 1 Diabetes

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sleep Self-Management
Sponsored by
Case Western Reserve University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type 1 Diabetes focused on measuring Young Adult

Eligibility Criteria

18 Years - 26 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1) Age range: from 18 to 25 years
  • 2) Diagnosed with T1D for at least 6 months
  • 3) No other major health problems (e.g., chronic medical condition or major psychiatric illness
  • 4) Not currently participating in any intervention studies
  • 5) Read/speak English
  • 6) Have a most recent A1C or eA1C value ≥ 7%.

Exclusion Criteria:

  • 1) Previous OSA diagnosis/high-risk sleep apnea
  • 2) Current pregnancy
  • 3) Night shift workers
  • 4) Habitually sleep > 7 hours on work or school days.

Sites / Locations

  • University Hospitals of Cleveland Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Sleep Self-Management

Diabetes Self-Management Education

Arm Description

The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.

The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.

Outcomes

Primary Outcome Measures

Repeated Measures
General Estimating Equation (GEE)
Non-dominant wrist-worn actigraph to be worn 24/7 (Spectrum Plus)
Change in sleep duration (longer sleep duration indicates improvement)
Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark]
Change in time in range and glucose variability (More time in range and less glucose variability indicates improvement)

Secondary Outcome Measures

Self-Care Inventory Revised (15-item)
Change in diabetes self-management (higher scores indicate improvement)
10-Minute Psychomotor Vigilance Test on a PVT-192 device
Change in PVT scores (lower score indicates improvement)
Paper-based Trail Making Test parts A and B (Executive Function)
Change in executive function (lower scores indicate improvement)
PROMIS v1.0 (8-item general distress-depression)
Change in general distress (lower scores indicate improvement)
Diabetes Distress Scale (17-item)
Change in diabetes distress (lower scores indicate improvement)
Diabetes Symptom Checklist Revised (34-item)
Change in diabetes physical symptoms (lower scores indicate improvement)

Full Information

First Posted
July 9, 2021
Last Updated
September 17, 2023
Sponsor
Case Western Reserve University
Collaborators
National Institute of Nursing Research (NINR), National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT04975230
Brief Title
Self-Management in Young Adults With Type 1 Diabetes
Acronym
SLEEPT1D
Official Title
Sleep, Glycemia, and Self-Management in Young Adults With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 29, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Case Western Reserve University
Collaborators
National Institute of Nursing Research (NINR), National Institutes of Health (NIH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Type 1 Diabetes (T1D) affects 1.6 million Americans, and only 14% of young adults age 18-25 years achieve glycemic targets (glycosylated hemoglobin A1C <7.0%). Achieving glycemic targets is associated with reduced risk for both micro-and macrovascular complications, better neurocognitive function, and better diabetes quality of life. In lab studies, sleep deprivation led to impaired glucose tolerance and insulin sensitivity in adults without chronic condition and in one study of adults with T1D. Extending sleep in natural environments contributes to improved insulin sensitivity and glucose levels, neurocognition, and psychological symptoms in young adults without chronic conditions. Modifiable dimensions of sleep health (appropriate sleep duration, stability, and timing) are associated with better glycemic control in adults with T1D. Therefore, improving sleep duration, stability, and timing may be potential therapeutic targets to improve glucoregulation and clinical outcomes (diabetes self-management, neurocognitive function, and symptoms) in this high-risk population. The overall objective is to test and compare the effects of a cognitive-behavioral sleep self-management intervention (sleep extension and consistency in sleep timing) compared to an attention control condition (habitual sleep duration + diabetes self-management education) on improving sleep duration, stability, and timing, and glycemia (glycemic control and glucose variability) in short-sleeping young adults with T1D in a pilot randomized controlled trial.
Detailed Description
This is a two-arm randomized controlled trial, with participants assigned to either the Sleep Self-Management arm or the attention control arm (Diabetes Self-Management Education). The Sleep Self-Management condition involves an initial 50-minute face-to-face consultation with brief 5-10 minute weekly follow-ups in a format TBD by aim 1 (e.g., call, text, video conference) with 3-week booster sessions in person. The Sleep Self-Management intervention activities are provided in addition to "usual care."

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Young Adult

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Behavioral: Sleep self-management
Masking
Participant
Masking Description
Both conditions will receive time-balanced sessions with the study team. Participants will not be told whether in the experimental condition or the condition delivering usual care until after the completion of the study.
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sleep Self-Management
Arm Type
Experimental
Arm Description
The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.
Arm Title
Diabetes Self-Management Education
Arm Type
No Intervention
Arm Description
The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.
Intervention Type
Behavioral
Intervention Name(s)
Sleep Self-Management
Intervention Description
Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
Primary Outcome Measure Information:
Title
Repeated Measures
Description
General Estimating Equation (GEE)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
Non-dominant wrist-worn actigraph to be worn 24/7 (Spectrum Plus)
Description
Change in sleep duration (longer sleep duration indicates improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark]
Description
Change in time in range and glucose variability (More time in range and less glucose variability indicates improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Secondary Outcome Measure Information:
Title
Self-Care Inventory Revised (15-item)
Description
Change in diabetes self-management (higher scores indicate improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
10-Minute Psychomotor Vigilance Test on a PVT-192 device
Description
Change in PVT scores (lower score indicates improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
Paper-based Trail Making Test parts A and B (Executive Function)
Description
Change in executive function (lower scores indicate improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
PROMIS v1.0 (8-item general distress-depression)
Description
Change in general distress (lower scores indicate improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
Diabetes Distress Scale (17-item)
Description
Change in diabetes distress (lower scores indicate improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention
Title
Diabetes Symptom Checklist Revised (34-item)
Description
Change in diabetes physical symptoms (lower scores indicate improvement)
Time Frame
From (T0) baseline through (T3) 90 days post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
26 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1) Age range: from 18 to 26 years 2) Diagnosed with T1D for at least 6 months 3) No other major health problems (e.g., chronic medical condition or major psychiatric illness 4) Not currently participating in any intervention studies 5) Read/speak English 6) Have a most recent A1C or eA1C value ≥ 7%. Exclusion Criteria: 1) Previous OSA diagnosis/high-risk sleep apnea 2) Current pregnancy 3) Night shift workers 4) Habitually sleep > 7 hours on work or school days.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephanie Griggs, PhD
Organizational Affiliation
Case Western Reserve University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals of Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106-4904
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Self-Management in Young Adults With Type 1 Diabetes

We'll reach out to this number within 24 hrs